Skip to main content

Advertisement

SpringerLink
Log in

A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin

  • Medical Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Survival after surgery for pancreas cancer remains low. This improves with adjuvant chemotherapy, but up to 30% patients do not receive the prescribed treatment. Neoadjuvant therapy may increase the proportion of patients who receive all treatment components, may downstage disease before surgery, and may provide early treatment of micrometastases. This randomized phase 2 study compares gemcitabine-based chemotherapy regimens to identify the most promising regimen for future study.

Methods

Fifty patients with potentially resectable pancreas lesions were enrolled onto the study. Twenty-four patients were randomized to gemcitabine (1000 mg/m2) every 7 days for 43 days; 26 patients were randomized to gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2), 7 to the original schedule (omitting day 22) and 19 to a revised schedule due to neutropenia (omitting days 15 and 36). The primary outcome measure was resection rate.

Results

Patients who were allocated to gemcitabine received a median of 85% of the planned dose. Patients who were allocated to combination treatment received a median of 88% and 92% of the planned gemcitabine and cisplatin doses, respectively. There were 10 episodes of grade III/IV hematological toxicity in each group. Twenty-seven patients (54%) underwent pancreatic resection, 9 (38%) in the gemcitabine arm and 18 (70%) in the combination arm, with no increase in surgical complications. To date, 34 patients (68%) have died. Twelve-month survival for the gemcitabine and combination groups was 42% and 62%.

Conclusions

Chemotherapy can be safely administered before pancreatic surgery. Combination therapy with gemcitabine and cisplatin is associated with a high resection rate and an encouraging survival rate, suggesting that further study is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50:7–33

    PubMed  CAS  Google Scholar 

  2. Ries LAG, Miller BA, Hankey BF, eds. SEER Cancer Statistics Review: Tables and Graphs. Bethesda, MD: National Cancer Institute, 1994

    Google Scholar 

  3. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Incidence, treatment and survival in 13,560 patients with pancreatic cancer: an epidemiological study in the West Midlands. Br J Surg 1995; 82:111–5

    Article  PubMed  CAS  Google Scholar 

  4. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg 1990; 211:447–58

    Article  PubMed  CAS  Google Scholar 

  5. Russell RC. Surgical resection for cancer of the pancreas. Baillieres Clin Gastroenterol 1990; 4:889–916

    Article  PubMed  CAS  Google Scholar 

  6. Gall FP, Kessler H, Hermanek P. Surgical treatment of ductal pancreatic carcinoma. Eur J Surg Oncol 1991; 17:173–81

    PubMed  CAS  Google Scholar 

  7. Andren-Sandberg A, Ahren B, Tranberg KG, Bengmark S. Surgical treatment of pancreatic cancer. The Swedish experience. Int J Pancreatol 1991; 9:145–51

    PubMed  CAS  Google Scholar 

  8. Edge SB, Schmieg R Jr, Rosenlof LK, Wilhelm MC. Pancreas cancer resection outcome in American university centers in 1989–1990. Cancer 1993; 71:3502–8

    Article  PubMed  CAS  Google Scholar 

  9. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreatoduodenectomies without mortality. Ann Surg 1993; 217:430–8

    Article  PubMed  CAS  Google Scholar 

  10. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221:59–66

    CAS  Google Scholar 

  11. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In: De Vita, Hellman S, Rosenberg SA, (eds). Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins, 2001:1126–61

  12. Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120:899–903

    Google Scholar 

  13. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999; 230:776–82

    Article  PubMed  CAS  Google Scholar 

  14. Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200–10

    Article  PubMed  CAS  Google Scholar 

  15. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15:928–37

    PubMed  CAS  Google Scholar 

  16. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225:621–33

    Article  PubMed  CAS  Google Scholar 

  17. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16:317–23

    PubMed  CAS  Google Scholar 

  18. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8:123–32

    Article  PubMed  CAS  Google Scholar 

  19. Brunner TB, Grabenbauer GG, Klein P, et al. Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003; 55:144–53

    Article  PubMed  CAS  Google Scholar 

  20. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171:118–24

    Article  PubMed  CAS  Google Scholar 

  21. Aristu J, Canon R, Pardo F, et al. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 2003; 26:30–6

    Article  PubMed  Google Scholar 

  22. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD. Phase II trial of gemcitabine in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12:29–34

    Article  PubMed  CAS  Google Scholar 

  23. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris A, Spiessl G. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1995; 73:101–5

    Google Scholar 

  24. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403–13

    PubMed  CAS  Google Scholar 

  25. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2:521–30

    PubMed  CAS  Google Scholar 

  26. Crul M, van Waardenburg RC, Bocxe S, et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003; 65:275–82

    Article  PubMed  CAS  Google Scholar 

  27. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non–small-cell lung cancer. J Clin Oncol 1999; 17:12–8

    PubMed  CAS  Google Scholar 

  28. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068–77

    PubMed  Google Scholar 

  29. Hussain SA, Stocken DD, Riley P, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 2004; 91:844–9

    PubMed  CAS  Google Scholar 

  30. Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11(11):1399–403

    Article  PubMed  CAS  Google Scholar 

  31. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92:569–77

    Article  PubMed  CAS  Google Scholar 

  32. Brodowicz T, Wolfram RM, Kostler WJ, et al. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 2000; 11:623–8

    Article  PubMed  CAS  Google Scholar 

  33. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 2002; 94:902–10

    Article  PubMed  CAS  Google Scholar 

  34. Heinemann V, Quietzsch D, Gieseler F, et al. A phase III trial comparing gemcitabine plus cisplatin vs gemcitabine alone in advanced pancreatic carcinoma (abstract 1003). Proc Am Soc Clin Oncol 2003;22

  35. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31–41

    Article  PubMed  CAS  Google Scholar 

  36. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69:1375–81

    PubMed  CAS  Google Scholar 

  37. Neuhaus P, Oettle H, Post S, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs observation in patients with resected pancreatic cancer (abstract 4013). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23(16S) Part I of II (June 1 suppl), 2005:4013

  38. Pisters PW, Hudec WA, Lee JE, et al. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 2000; 18:860–7

    PubMed  CAS  Google Scholar 

  39. Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991; 161:26–9

    Article  PubMed  CAS  Google Scholar 

  40. Hyoty MK, Mattila JJ, Salo K, Nordback IH. Intraoperative fine needle aspiration cytologic examination of pancreatic lesions. Surg Gynecol Obstet 1991; 173:193–7

    PubMed  CAS  Google Scholar 

  41. Jarufe NP, Coldam C, Mayer AD, Mirza DF, Buckels JAC, Bramhall SR. Favourable prognostic factors in a large UK experience of adenocarcinoma of the head of the pancreas and periampullary region. Dig Surg 2004; 21:202–9

    Article  PubMed  CAS  Google Scholar 

  42. Gudjonsson B. Cancer of the pancreas 50 years of surgery. Cancer 1987; 60:2284–303

    Article  PubMed  CAS  Google Scholar 

  43. Baumel H, Huguier M, Manderscheid JC, Fabre JM, Houry S, Fagot H. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg 1994; 81:102–7

    Article  PubMed  CAS  Google Scholar 

  44. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161:120–4

    Article  PubMed  CAS  Google Scholar 

  45. Funovics JM, Karner J, Pratschner T, Fritsch A. Current trends in the management of carcinoma of the pancreatic head. Hepatogastroenterology 1989; 36:450–5

    PubMed  CAS  Google Scholar 

  46. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217:144–8

    Article  PubMed  CAS  Google Scholar 

  47. Lillemoe KD, Cameron JL, Yeo CJ, et al. Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 1996; 223:718–25

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Supported by Eveson Charitable Trust (Registered Charity 1032204) and from an educational grant from Eli Lilly. We thank V. Archer, P. Mulholland, D. Mirza, D. Mayer, D. Candinas, J. Oliff, and S. Hussain for their support for the study and their help preparing the manuscript.

Author information

Authors and Affiliations

  1. Cancer Research UK Institute for Cancer Studies and Clinical Trials Unit, University of Birmingham, Vincent Drive, Birmingham, B15 2TT, United Kingdom

    Daniel H. Palmer MRCP, PhD, Deborah D. Stocken PhD, Helen Hewitt RGN, A. Bassim Hassan PhD & Philip J. Johnson FRCP, MD

  2. The Liver Unit, Queen Elizabeth Hospital, Birmingham, B15 2TH, United Kingdom

    Catherine E. Markham RGN, John A. C. Buckels FRCS, MD & Simon R. Bramhall FRCS, MD

Authors
  1. Daniel H. Palmer MRCP, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah D. Stocken PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helen Hewitt RGN
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catherine E. Markham RGN
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Bassim Hassan PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Philip J. Johnson FRCP, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John A. C. Buckels FRCS, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Simon R. Bramhall FRCS, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel H. Palmer MRCP, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palmer, D.H., Stocken, D.D., Hewitt, H. et al. A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin. Ann Surg Oncol 14, 2088–2096 (2007). https://doi.org/10.1245/s10434-007-9384-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9384-x

Keywords

Search

Navigation